Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
Sell
48
GMED Quote, Financials, Valuation and Earnings
Last price:
$71.13
Seasonality move
:
3.13%
Day range:
$71.81 - $73.45
52-week range:
$49.33 - $94.93
Dividend yield:
0%
P/E ratio:
96.47x
P/S ratio:
3.95x
P/B ratio:
2.38x
Volume:
763.4K
Avg. volume:
1.4M
1-year change:
39.62%
Market cap:
$10B
Revenue:
$2.5B
EPS (TTM):
$0.75
Analysts' Opinion
-
Consensus RatingGlobus Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $97.46, Globus Medical has an estimated upside of 34.71% from its current price of $72.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $80.00 representing -10.57% downside risk from its current price of $72.35.
Fair Value
-
According to the consensus of 10 analysts, Globus Medical has 34.71% upside to fair value with a price target of $97.46 per share.
GMED vs. S&P 500
-
Over the past 5 trading days, Globus Medical has overperformed the S&P 500 by 2.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Globus Medical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Globus Medical has grown year-over-year revenues for 18 quarters straight. In the most recent quarter Globus Medical reported revenues of $657.3M.
Earnings Growth
-
Globus Medical has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Globus Medical reported earnings per share of $0.19.
Enterprise value:
9.5B
EV / Invested capital:
--
Price / LTM sales:
3.95x
EV / EBIT:
43.26x
EV / Revenue:
3.77x
PEG ratio (5yr expected):
--
EV / Free cash flow:
23.46x
Price / Operating cash flow:
24.56x
Enterprise value / EBITDA:
20.06x
Gross Profit (TTM):
$1.5B
Return On Assets:
2.03%
Net Income Margin (TTM):
4.09%
Return On Equity:
2.56%
Return On Invested Capital:
2.31%
Operating Margin:
11.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1B | $1.6B | $2.5B | $616.5M | $657.3M | |
| Gross Profit | $759.1M | $1B | $1.5B | $351M | $393.9M | |
| Operating Income | $236.3M | $201.9M | $219.7M | $26M | $77.1M | |
| EBITDA | $304.5M | $346.6M | $473.7M | $97.1M | $145.3M | |
| Diluted EPS | $1.86 | $1.17 | $0.75 | $0.11 | $0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $821.8M | $864.5M | $983.3M | $1.9B | $2.2B | |
| Total Assets | $1.7B | $2B | $2.1B | $5.1B | $5.3B | |
| Current Liabilities | $120.8M | $140.2M | $159.2M | $392.3M | $855.9M | |
| Total Liabilities | $173.2M | $215.9M | $229.8M | $1.1B | $1.1B | |
| Total Equity | $1.5B | $1.7B | $1.8B | $4B | $4.2B | |
| Total Debt | -- | -- | -- | $417.4M | $443.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $178.5M | $243.5M | $520.6M | $104.7M | $210.3M | |
| Cash From Investing | -$110.4M | $303M | -$176.1M | $320.6M | -$104.1M | |
| Cash From Financing | -$110M | -$231.8M | -$27.7M | -$237.3M | $59.7M | |
| Free Cash Flow | $104.4M | $165.2M | $405.2M | $81.8M | $193.2M | |
GMED
Sector
Market Cap
$10B
$35M
Price % of 52-Week High
76.21%
41.88%
Dividend Yield
0%
0%
Shareholder Yield
0.7%
-0.91%
1-Year Price Total Return
39.62%
-43.29%
Beta (5-Year)
1.284
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$71.43
200-day SMA
Sell
Level
$76.79
Bollinger Bands (100)
Sell
Level
75.15 - 88.43
Chaikin Money Flow
Buy
Level
52.6M
20-day SMA
Sell
Level
$72.98
Relative Strength Index (RSI14)
Sell
Level
46.63
ADX Line
Sell
Level
29.27
Williams %R
Neutral
Level
-33.4326
50-day SMA
Sell
Level
$78.00
MACD (12, 26)
Sell
Level
-1.47
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
85.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.5743)
Buy
CA Score
(Annual)
Level (1.2527)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.7057)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Stock Forecast FAQ
In the current month, GMED has received 6 Buy ratings 4 Hold ratings, and 0 Sell ratings. The GMED average analyst price target in the past 3 months is $97.46.
-
Where Will Globus Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Globus Medical share price will rise to $97.46 per share over the next 12 months.
-
What Do Analysts Say About Globus Medical?
Analysts are divided on their view about Globus Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Globus Medical is a Sell and believe this share price will drop from its current level to $80.00.
-
What Is Globus Medical's Price Target?
The price target for Globus Medical over the next 1-year time period is forecast to be $97.46 according to 10 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is GMED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Globus Medical is a Buy. 6 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GMED?
You can purchase shares of Globus Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Globus Medical shares.
-
What Is The Globus Medical Share Price Today?
Globus Medical was last trading at $71.13 per share. This represents the most recent stock quote for Globus Medical. Yesterday, Globus Medical closed at $72.35 per share.
-
How To Buy Globus Medical Stock Online?
In order to purchase Globus Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
45
DSDVY alert for Apr 16
DSV AS [DSDVY] is down 2.69% over the past day.
Buy
76
PDEX alert for Apr 16
Pro-Dex [PDEX] is down 4.66% over the past day.
Buy
82
HAGHY alert for Apr 16
Hensoldt AG [HAGHY] is down 0.02% over the past day.
